srRNA technology allows us to rapidly develop effective, low-dose vaccines for complex infectious disease targets.
LEARN MORE ABOUT COMPLEX INFECTIOUS DISEASePipeline
ENABLING BROAD APPLICATIONS FOR RNA TREATMENTS
Replicate is advancing a robust pipeline of srRNA treatments spanning several therapeutic areas. Our pipeline achieves initial clinical proof of concept in infectious disease, demonstrating a best-in-class technology, advances a first-in-class oncology candidate to IND, and demonstrates the potential of the technology with two candidate selections in major therapeutic areas with clear preclinical inflection points.
Program
Indication & Mechanism
Discovery
Preclinical
Clinical – Phase 1
Clinical – Phase 2
Infectious Disease
RBI-4000
Prophylactic Rabies Vaccine
Viral Glycoprotein
CLINICAL – PHASE 1
RBI-5000
Prophylactic EBV Vaccine
Undisclosed
DISCOVERY
Oncology
Targeted cancer therapy often results in predictable mutations that lead to drug resistance. Precision immuno-oncology is our approach to treating cancer by preventing clinical resistance from developing. Our srRNAs educate the immune system to recognize and remove common mutations, extending the time that people with cancer may benefit from a targeted therapy.
LEARN MORE ABOUT PRECISION IMMUNO-ONCOLOGyRBI-1000
Breast Cancer
Endocrine Therapy Resistance
IND-enabling
RBI-3000
Lung Cancer
Targeted Therapy Resistance
DISCOVERy
Immunology
Autoimmune diseases are often driven by the overexpression of inflammatory molecules. Current approaches struggle to quell this over-activity. Our pipeline includes srRNA-encoded molecules that halt the pathways that drive inflammatory and autoimmune diseases by targeting downstream mediators of the inflammasome.
RBI-8000
Autoimmunity
Inflammasome
DISCOVERY
Clinical trial information
Replicate is currently studying RBI-4000 in a Phase 1 clinical trial to evaluate clinical proof of concept, safety, and tolerability in humans. To find out more about the trial and eligibility, visit:
